This trial is testing a new cancer drug, zanidatamab, to see if it is safe and effective for treating certain types of gastrointestinal cancers. Eligible patients have cancer that has spread and cannot be removed by surgery.
4 Primary · 12 Secondary · Reporting Duration: Up to 2 years
362 Total Participants · 5 Treatment Groups
Primary Treatment: ZW25 (Zanidatamab) · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: